Randomized Controlled trials (RCTs) to treat CMI. Studies have shown global and regional functional improvements in Patients with Chronic Myocardial Infarction (CMI). The included studies met the following criteria: RCTs, CMI patients who received Coronary Artery Bypass Graft (CABG), BMSC were infused intramuscularly, cell injection in peri-infarct zone, and studies that had up to 6 month follow-up. The initial search identified 8,433 references, of which 7 RCTs met the inclusion criteria. Selected bone marrow stem cells were injected in three of the 7 trials while unselected BMSC was injected to the treatment group in the rest 4 trials. The treatment effects of the studies in which the treatment group was injected with CD34+ and CD133+ were greater than the studies that used unselected BMSC (7.66%, 95% CI: 4.16-11.15 vs. 4.77%; 95% CI: 2.08-7.46). Planned sub-group analyses revealed that the treatment effects on improvement in LVEF differed according to the measurement tools used on outcome assessment, treatment blindness, and methods of surgery. Selected BMSC appeared to show more effective than unselected BMSC. However, the intervention effect of selected BMSC might be overestimated because the studies tended to use less rigorous designs, less precise outcome measures, and different methods of surgery than those using unselected BMSC. Therefore these treatment effects of selected BMSC should be interpreted cautiously.

Keywords: Bone marrow stem cell; Chronic myocardial infarction; Systematic review

Abbreviations: BMSC: Bone Marrow Stem Cell; CMI: Chronic Myocardial Infarction; CABG: Coronary Artery Bypass Graft; LVEF: Left Ventricular Ejection Fraction; MRI: Magnetic Resonance Imaging; SPECT: Single Photon Emission Computed Tomography; OPCAB: Off-pump Coronary Artery Bypass Grafting; RCTs: Randomized Controlled Trials

Introduction

Studies have shown global and regional functional improvements after Bone Marrow Stem Cell (BMSC) have been injected into viable, peri-infarct areas of chronically ischemic myocardium [1-3]. Bone marrow-derived CD34+ and CD 133+ cells, which exhibit endothelial phenotypes, have been shown to contribute to neovascularization. Also, intramyocardial injection of purified CD133+ BMSC that was involved in their direct application into the diseased myocardium at the time of Coronary Artery Bypass Graft (CABG). Bone marrow or mobilized peripheral blood progenitor cells might play a role in the revascularization of the ischemic myocardium [4]. Those features may explain the improved Left Ventricular Ejection Fraction (LVEF) in patients with Chronic Myocardial Infarction (CMI). It has been shown that selected BMSC were more effective than unselected BMSC in the infarcted myocardium However, the therapeutic efficacy remains controversial. Therefore we conducted a systematic review to examine the effectiveness of selected BMSC on improving LVEF from Randomized Controlled trials (RCTs) to treat CMI.

Methods

Data search

We searched Medline from 1946 to March 2012 for studies of BMSC transplantation in patients with CMI. The included studies met the following criteria: randomized controlled trials, CMI patients who received CABG, BMSC were infused intramuscularly, cell injection in peri-infarct zone, and studies that had up to 6 month follow-up to assess the short-term effect of BMSC transplantation.

Data extraction

Two investigators (HJ and HWY) independently screened all titles and abstracts to identify studies that met the inclusion criteria and extracted relevant data, with divergences resolved by consensus.

*Corresponding author: Hyeon Woo Yim, MD, PhD, Professor, Department of Preventive Medicine, The Catholic University of Korea College of Medicine, 505 Banpo-dong, Seocho-gu, Seoul, Republic of Korea, Tel: +82-2-2258-7860; Fax: +82-2-2258-3820; E-mail: y1693@catholic.ac.kr

Received December 26, 2013; Accepted January 23, 2014; Published January 25, 2014


Copyright: © 2014 Jeong H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The details extracted were the study and patient population numbers and characteristics, the type of BMSC, cell dose, baseline LVEF, tools of outcome assessment, whether or not sham injection in the control group, and surgical methods. The outcome data extracted the changes in LVEF from the baseline to 6-month follow-up measured by echocardiography, Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography (SPECT), or left ventricular angiography. Clinical trials with multiple publications and sequential follow-up durations or different outcomes were considered to be one study.

Quality assessment

Two authors (HJ and HWY) independently assessed the risk of bias for each included study using criteria based on the Cochrane Handbook for Systematic Reviews of Interventions, the principle components of which are sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting bias [5]. Disagreements were resolved by discussion between the two authors. Assessment of methodological quality in terms of blindness was assessed by whether or not the control group patients were infused with placebo such as serum or plasma.

Statistical analysis

All statistics in this meta-analysis were performed using Review Manager Version 5.1 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) [5]. To calculate overall treatment effects weighted mean differences and 95% confidence intervals were presented. Data were pooled by use of the DerSimonian-Laird random-effects weighted mean differences. The statistical heterogeneity was analyzed with the $I^2$ statistic, and heterogeneity was defined as low (25-50%), moderate (50-75%), or high (>75%). For studies that did not report the actual change from baseline to 6-month follow-up, the change in Standard Deviation (SD) was calculated with a standardized formula used to calculate changes in mean and standard deviation.

Results

The initial search identified 8,433 references, of which 7 RCTs were, met the inclusion criteria (Figure 1).

The characteristics of the included studies are summarized in Table 1. Three of 7 trials injected selected bone marrow stem cell such as, CD34+ and CD133+ cells [3,7,8] and 4 of 7 trials injected unselected BMSC to the treatment group [9-12]. The treatment effects of the studies in which the treatment group was injected with CD34+ and CD133+ cells (LVEF change of 7.66%, 95% CI: 4.16-11.15) were greater than the studies that used unselected BMSC (LVEF change of 4.77%, 95% CI: 2.08-7.46) (Figure 2).

Table 2 described the methodological quality of RCTs.

Subgroup analyses and investigating heterogeneity

Subgroup analyses were carried out to assess the impact of the methods used on outcome measure-MRI or echocardiography, the treatment blindness-whether or not the control group patients were infused with placebo such as serum or plasma, and the methods of surgery-conventional CABG or off-pump CABG. Three trials were measured by MRI [9-11] and the other four were measured by echocardiography to assess the LVEF [3,7,8,12]. LVEF changes indicated that the treatment effects of the studies that used echocardiography as the outcome measure were greater than those of the studies that used MRI (WMDs: 8.02% (95% CI: 5.28-10.77) vs. 3.62% (95% CI: 0.71-6.53)). No statistical heterogeneity was found in the MRI analysis ($I^2$=0%) and moderate statistical heterogeneity was observed in echocardiography ($I^2$=45%).

We also looked at whether or not control group patients were infused with placebo to ensure health care providers remained blind to the study conditions. Three of the 7 trials were infused placebo injection [10-12] and the four remaining trials were not infused with anything in the control group [3,7-9]. The trials without placebo in the control group showed more improvements in LVEF by 8.59% (95% CI: 6.49-10.69) than those infused serum (LVEF change of 6.35%, 95% CI: 2.29-10.40). A low degree of statistical heterogeneity was found among the placebo injection studies ($I^2$=3%). However, there was substantial heterogeneity in the studies without placebo injection in the control group ($I^2$=79%).

Among the 7 trials, 6 of them used conventional CABG in stem cell transplantation [3,9-12] and only 1 trial used off-pump CABG (OPCAB) [7]. When a subgroup analysis was conducted using only the 5 conventional CABG studies without the 1 OPCAB, the heterogeneity disappeared ($I^2$=0%) (Table 3). In addition, sensitivity analyses were conducted to estimate the effect of randomization and allocation concealment on LVEF. However, the discrepancies were negligible.
that the treatment effects of stem cell therapy in patients with acute MI among the included trials. Our previous finding seemed to indicate a role in successful engraftment of BMC in infarcted cardiac tissue [14]. Those findings suggest that the CD34+ cells may play an important role in neovascularization and to be differentiated into the endothelial cells in the rat model [13]. In addition, Hofmann et al. [14] have shown that 14% to 39% of a CD34-enriched population homed into infarcted sites of neovascularization and to be differentiated into the endothelial cells in the rat model [13]. In addition, Hofmann et al. [14] have shown that 14% to 39% of a CD34-enriched population homed into infarcted myocardium after intramyocardial BMSC transplantation for CMI patients, which was indicated by improved LVEF. These findings are consistent with the results suggested a potential improvement of heart function after intramyocardial BMSC transplantation for CMI patients, which was indicated by improved LVEF. These findings are consistent with the improvement of the myocardium after stem cell transplantation. To measure treatment effect of stem cell therapy after adjusting for the previously known confounding factors through subgroup analyses according to whether the outcome assessment tool was MRI or echocardiography, whether or not a sham injection was used in the control group, and what type of the surgery method was used.

The assessment of cardiac function is essential for determining the improvement of the myocardium after stem cell transplantation. To measure treatment effect of stem cell therapy on cardiac function for patients with CMI, many researchers used a various aspects of regional myocardial function, such as improvements in global strain and global strain rate, changes in segmental myocardial strain and strain rate, changes in infarct size, regional wall motion, and wall thickening, peak oxygen consumption, 6-minute walk test, and New York Heart Association functional classification. To measure treatment effects of the stem cell therapy on the cardiac function for patients with CMI, various aspects of the regional myocardial function should be considered as well as improvement in the LV systolic and diastolic cardiac function. The diastolic function was influenced by cell necrosis, residual ischemia, microvascular dysfunction, and regional wall motion abnormalities. Exercise capacity is also an important outcome measure of the stem cell therapy on the cardiac function for patients with CMI.

Discussion

We wanted to directly compare the differences between the selected versus unselected stem cells in the stem-cell treatments for CMI patients. Selected BMSC appeared to show more effective than unselected BMSC (WMDs in LVEF 7.66% vs. 4.77%). Our results suggested a potential improvement of heart function after intramyocardial BMSC transplantation for CMI patients, which was indicated by improved LVEF. These findings are consistent with the improvement of the myocardium after stem cell transplantation. To measure treatment effect of stem cell therapy after adjusting for the previously known confounding factors through subgroup analyses according to whether the outcome assessment tool was MRI or echocardiography, whether or not a sham injection was used in the control group, and what type of the surgery method was used.

The assessment of cardiac function is essential for determining the improvement of the myocardium after stem cell transplantation. To measure treatment effect of stem cell therapy on cardiac function for patients with CMI, many researchers used a various aspects of regional myocardial function, such as improvements in global strain and global strain rate, changes in segmental myocardial strain and strain rate, changes in infarct size, regional wall motion, and wall thickening, peak oxygen consumption, 6-minute walk test, and New York Heart Association functional classification. To measure treatment effects of the stem cell therapy on the cardiac function for patients with CMI, various aspects of the regional myocardial function should be considered as well as improvement in the LV systolic and diastolic cardiac function. The diastolic function was influenced by cell necrosis, residual ischemia, microvascular dysfunction, and regional wall motion abnormalities. Exercise capacity is also an important outcome measure of the stem cell therapy on the cardiac function for patients with CMI.
measure to assess the myocardial function after MI. Even though those are important functional outcome measures for CMI, they often make it difficult to compare among their effect sizes directly because not all studies used all of them. LVEF has been known as a conventional predictor of the myocardial function [16].

The detection of MI in echocardiography showed relatively low sensitivity as well as inter-personal and intra-personal variability [17]. However, MRI has several important advantages over the other methods for detecting MI, because of its superior spatial resolution and tissue contrast and the unique ability to detect small infarctions that might otherwise be missed in a routine clinical practice using ECG or echocardiography [18]. Because the effects of stem cell therapy are measured by micro-functional improvement in myocardium, a more precise tool may be better for measuring the myocardial function. Moreover, all of the included studies assessed global LVEF as their primary outcome to evaluate the effects of stem cell therapy. Therefore, to increase the comparability we analyzed the changes in global myocardial function to investigate the effect of stem cell transplantation. Global assessment of myocardial function was widely performed by estimating the LVEF using echocardiography or MRI in the included studies. Three trials were measured by MRI and the other four were by echocardiography to assess the LVEF in the present meta-analysis. Up until 6 months of follow-up period there were statistically significant differences LVEF mean change from the baseline measured by both echocardiography and MRI. However, the magnitudes of the improvement were greater with echocardiography than with MRI. This finding was consistent with one of the previous meta-analyses of stem cell treatment for patients with acute myocardial infarction [19].

Clinical trials of stem cell therapy should be strictly designed as it is very difficult to maintain blinding throughout the entire research period, even when research is designed with double-blind controlled trials [20]. We classified the studies into whether or not control group patients were infused with placebo to ensure health care providers remained blind to the study conditions. Three of the 7 trials were infused placebo injection and the four remaining trials were not infused with anything in the control group. The trials without placebo injection in the control group showed more improvements in LVEF than with infused ones. When it comes to the importance of blindness in conducting stem cell transplant to restore the heart function was published recently [15]. Unblinded design might lead to overestimate the treatment effects.

The surgical methods were also one of the important factors of treatment effect. Among the 7 trials, 6 of them used conventional CABB in stem cell transplantation and only 1 trial used OPCAB. The mean changes in LVEF between the baseline and 6 month follow-up were greater OPCAB than conventional CABB.

All of the studies in which the treatment group injected selected CD34+ and CD133+ BMSC assessed the outcome measure with echocardiography and did not infused with anything in the control group. Selected BMSC appeared to be more effective in CMI patients but other factors might have compounded the results. The randomized controlled trial is generally regarded as a stronger study design for assessing benefits or harms of health care interventions. However, randomization in itself does not guarantee that trial results are valid. Methodological issues affecting the validity of randomized controlled trials can occur because all of the data did not come out of double-blind trials. When it comes to choosing measurement tools, efforts should be made to minimize inter-observer variation which is prone to bias. It is, therefore, not surprising that many studies have found such trials overestimating the treatment effects by a substantial degree when compared with well designed randomized controlled trials. A less rigorous RCT study in which allocation concealments was not kept throughout the study or the measurement tool was not appropriate compared to a well designed study with an objective measurement tool may overestimate the study results. The measurement tools vulnerable to inter-rater variability can also affect the study results. These factors may work as confounders of the study overestimating its effect size.

A systematic review attempts to search all empirical evidence in order to answer a specific research question. The meta-analysis combines results from several different primary studies in order to provide more precise and valid results. In addition to heterogeneity could be explored by conducting subgroup analysis or meta-regression to explain the sources of the heterogeneity since methodological diversity creates heterogeneity through biases variably affecting the results of different studies [5,21,22].

There were some of the limitations. One of the limitations was the small number of studies included in the meta-analysis. Due to the small sample size, we could not conduct a meta-regression to estimate the confounding effects. Second, the changes of LVEF only used for the comparison of myocardial function between selected and unselected stem cells based on the available data.

In conclusion, selected BMSC tended to show more effective than unselected BMSC. The intervention effect of selected BMSC might be overestimated due to the fact that the studies tended to use less rigorous designs, less precise outcome measures, and different methods of surgery than those using unselected BMSC. Therefore these treatment effects of selected cell type should be interpreted cautiously.

Acknowledgements

This research was supported by a grant (10172MFDS993) from Ministry of Food & Drug Safety in 2013.

References


